Sunday, November 22, 2026

Kelun-Biotech Advances 30+ Oncology Candidates as ADC Pipeline Race Accelerates Through 2027

Chinese biotech Kelun-Biotech is advancing 30+ oncology candidates including novel antibody-drug conjugates (ADCs) as major pharmaceutical companies push targeted therapies through late-stage trials. Regulatory milestones concentrated in 2026-2027 signal an intense approval cycle for cancer treatments, with established players Pfizer, Regeneron, and BioNTech competing across multiple cancer types.

This article was written by AI. Built from the source documents listed below. How we work

Kelun-Biotech Advances 30+ Oncology Candidates as ADC Pipeline Race Accelerates Through 2027
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Kelun-Biotech is advancing 30+ oncology candidates through clinical trials, positioning the Chinese biotech as a major competitor in the accelerating antibody-drug conjugate (ADC) market.1 The expanded pipeline coincides with concentrated regulatory milestones from 2026-2029, creating a competitive approval cycle for cancer therapies.

BioNTech presented clinical data at ELCC 2026 for pumitamig, gotistobart, and a HER3-targeted ADC across lung cancer settings.2 "We continue to advance differentiated treatment approaches across lung cancer settings while building the clinical evidence to guide their further development," said Prof. Özlem Türeci, BioNTech's Chief Medical Officer.2

Regeneron secured Japanese approval for Dupixent in bullous pemphigoid, expanding the IL-4/IL-13 pathway inhibitor beyond previous indications.3 The fully human monoclonal antibody represents Regeneron's push into dermatological conditions with targeted immunology.

Silexion Therapeutics received Israeli Ministry of Health approval for a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, where KRAS mutations appear in over 90% of cases.4 The trial follows positive Phase 2a results for predecessor drug Loder versus chemotherapy alone.4

The convergence of late-stage oncology programs from Chinese biotechs and Western pharma creates near-term catalysts for healthcare investors. ADC platforms target specific tumor antigens while minimizing systemic toxicity, addressing a key limitation of traditional chemotherapy.

Ascentage Pharma and Terns Pharmaceuticals also advanced oncology programs through regulatory processes in March 2026, though specific trial data was not disclosed.5 The cluster of activity from 2026-2027 suggests overlapping approval timelines that will determine market share across cancer subtypes.

For market-focused investors, the oncology pipeline acceleration presents sector rotation opportunities as trial readouts and regulatory decisions drive volatility in individual biotech names through 2027.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: High
  1. [1]Press releaseGlobeNewswire· March 25, 2026
    Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
  2. [2]Press releaseGlobeNewswire· March 24, 2026
    BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
  3. [3]Press releaseGlobeNewswire· March 24, 2026
    Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse
  4. [4]News articleYahoo Finance· March 24, 2026
    KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
  5. [5]Press releaseGlobeNewswire· March 25, 2026
    Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
  6. [6]Press releaseGlobeNewswire· March 24, 2026
    Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
  7. [7]Press releaseGlobeNewswire· March 25, 2026
    Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
  8. [8]Press releaseGlobeNewswire· January 12, 2026
    BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026
  9. [9]News articleYahoo Finance· November 6, 2025
    Bio-Techne (TECH) Q1 2026 Earnings Call Transcript
  10. [10]Press releaseGlobeNewswire· November 27, 2025
    CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi
  11. [11]Press releaseGlobeNewswire· November 7, 2025
    Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
  12. [12]Earnings callNasdaq· November 27, 2025
    Corcept (CORT) Q3 2025 Earnings Call Transcript

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 12 source documents from 3 publications, dated 6 Nov 2025 to 25 Mar 2026
  2. Published 26 Mar 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.